206 related articles for article (PubMed ID: 30740787)
1. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
Ishitsuka K; Yurimoto S; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Eur J Haematol; 2019 May; 102(5):407-415. PubMed ID: 30740787
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
Ishitsuka K; Yurimoto S; Kawamura K; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
Int J Hematol; 2017 Oct; 106(4):522-532. PubMed ID: 28597329
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
[TBL] [Abstract][Full Text] [Related]
4. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
5. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
6. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
7. Mogamulizumab
Phillips AA; Fields PA; Hermine O; Ramos JC; Beltran BE; Pereira J; Wandroo F; Feldman T; Taylor GP; Sawas A; Humphrey J; Kurman M; Moriya J; Dwyer K; Leoni M; Conlon K; Cook L; Gonsky J; Horwitz SM;
Haematologica; 2019 May; 104(5):993-1003. PubMed ID: 30573506
[TBL] [Abstract][Full Text] [Related]
8. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
9. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
[TBL] [Abstract][Full Text] [Related]
12. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
[TBL] [Abstract][Full Text] [Related]
13. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
[TBL] [Abstract][Full Text] [Related]
14. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
[TBL] [Abstract][Full Text] [Related]
16. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
Iida S; Ishida T; Ueda R
Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
19. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
[TBL] [Abstract][Full Text] [Related]
20. [Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab].
Yamanaka S; Nakayama K; Tamai H; Sakamaki M; Inokuchi K
Rinsho Ketsueki; 2017; 58(4):309-314. PubMed ID: 28484158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]